Cholecystokinin-2 (CCK-2) receptors represent an important molecular target overexpressed on a range of cancers, and particularly neuroendocrine tumor (NET) with low or absent somatostatin receptor subclass-2 (SSTR-2) expression. This evidence concerns the gene SSTR2 and neuroendocrine neoplasm.